Heart Failure
Webinar SGLT2i in ESC HF Guidelines vs. Real Practice
Dear Doctor,
Boehringer Ingelheim, in collaboration with the 2nd Department of Internal…
Mechanisms of Cardioprotective Effects of SGLT2 Inhibitors
Inhibitors of sodium-glucose cotransporter 2 (SGLT2i, gliflozins) are a relatively new group…
Basic Cardiovascular Benefits of the Oral Antidiabetic Medication Empagliflozin
Type 2 diabetes mellitus is one of the main risk factors for cardiovascular (CV) diseases.…
Heart Failure in the Light of New ESC Guidelines
Dear Doctor, The Czech Society of Internal Medicine of ČLS JEP invites you to watch the…
Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk
Type 2 diabetes mellitus (DM2) is a serious chronic metabolic disease whose prevalence has…
Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease
Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It…
Subscribe
E-courses on this topic
Conferences news
Go to records
Most read on this topic
- Empagliflozin Secures Reimbursement for Heart Failure Treatment
- Empagliflozin will be funded from May for symptomatic heart failure regardless of EF LK value
- Cardio-renal-metabolic syndrome in context
- Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk
Journal on this topic
Related topic